January 22nd, 2014
Announcing Janssen Global Public Health
As a company, and as global citizens, we have a responsibility to create new approaches, test new solutions, and collaborate with the best minds to help address today’s greatest public health challenges. At the heart of this commitment are the people we serve – those in need of new and improved health solutions, and those working diligently at the front-line to provide healthcare.
Today, we are very pleased to publicly announce a new and exciting step in Janssen’s commitment – the formation of the Janssen Global Public Health (Janssen GPH) group dedicated to sustainably advancing global public health worldwide. Our family of companies has a longstanding commitment to support comprehensive efforts toward strengthening the health of communities, improving maternal and child health, and preventing the spread of infectious and preventable diseases worldwide through vaccination. Janssen GPH is the next step in Janssen’s and Johnson & Johnson’s response to the world’s global public health challenges.
The vision for Janssen GPH is simple: improve global healthcare by harnessing the power of our health innovations to transform the lives of more people in more places, regardless of where they live or their ability to pay. To solve today’s greatest public health challenges, we recognize the need to bring the full force of our expertise, resources and capacity to global public health settings in equal measure to more established markets. Janssen GPH’s dedicated team will align groundbreaking science and innovative access models to improve health and drive change in the lives of individuals, families, and entire communities.
Janssen GPH will be responsible for clinical and product development for a growing portfolio of medicines, diagnostic tools, and health solutions; cultivate innovative pricing and financing models; and forge collaborations that strengthen our collective ability to advance public health solutions for the long-term.
At Janssen, we are constantly striving to develop new approaches, medicines, and tools to make the world a healthier place. But we need to do more than simply create. We need to implement. We need to make sure that everything we do in a research laboratory reaches the people who need it. This is the impetus beyond Janssen GPH. We have a responsibility to help address seemingly intractable health challenges, and we hope that Janssen GPH and the outcomes that stem from it will bring us one step closer to improving health for all.
As Janssen GPH continues to take shape, we look forward to sharing more on our efforts to better serve these needs.
Dr. Paul Stoffels is Chief Scientific Officer, and Worldwide Chairman, Pharmaceuticals, Johnson & Johnson. In this role, he works with R&D leaders across Johnson & Johnson to set the enterprise-wide innovation agenda and is a member of the Johnson & Johnson Executive Committee. He began his career as a physician in Africa, focusing on HIV and tropical diseases research. Paul chairs the Johnson & Johnson R&D Management Committee and provides oversight to the Johnson & Johnson Development Corporation (JJDC) and the Johnson & Johnson innovation centers, with the goal of catalyzing innovative science and technology.